This site is intended only for healthcare professionals resident in India
Menu
Close
Menu
Close
Pharmacotherapeutic group: Antithrombotic agents, direct factor Xa inhibitors, ATC code: B01AF025
Apixaban is a potent, oral, reversible, direct and highly selective active site inhibitor of factor Xa. It does not require antithrombin III for antithrombotic activity. Apixaban inhibits free and clot-bound factor Xa, and prothrombinase activity. Apixaban has no direct effects on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting factor Xa, apixaban prevents thrombin generation and thrombus development. Preclinical studies of apixaban in animal models have demonstrated antithrombotic efficacy in the prevention of arterial and venous thrombosis at doses that preserved haemostasis.5
Prevention of stroke and SE in adult patients with NVAF, including those with one or more risk factors, such as prior stroke or TIA, age ≥75 years, hypertension, diabetes mellitus and symptomatic heart failure (NYHA Class ≥II). Compared with warfarin, apixaban also results in less bleeding, including intracranial haemorrhage.5
Prevention of VTE in adult patients who have undergone elective hip or knee replacement surgery.5
Treatment of DVT and PE, and prevention of recurrent DVT and PE in adult patients.5
DVT, deep vein thrombosis; NVAF, non-valvular atrial fibrillation; NYHA, New York Heart Association; PE, pulmonary embolism; SE, systemic embolism; TIA, transient ischaemic attack; VTE, venous thromboembolic event; Xa, xaban.
References:
Disclaimer: The products discussed herein may have different product labelling in different countries. The product information provided in this site is intended only for the residents of India.
Please click the Prescribing Information link to view the safety and adverse events information of Eliquis®.
For the use only of Registered Medical Practitioners, or a hospital or a laboratory.
PP-ELI-IND-1567 25 July 2022
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.